Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma
Status:
Terminated
Trial end date:
1999-03-29
Target enrollment:
Participant gender:
Summary
Current therapies for Metastatic, Recurrent, or Refractory Neuroblastoma provide very limited
benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it
may prove beneficial in the treatment of Metastatic, Recurrent, or Refractory Neuroblastoma.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Metastatic, Recurrent, or Refractory
Neuroblastoma.